SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR

YARW

Related stories